title: T-cell prolymphocytic leukemia: a single-institution experience.
abstract: BACKGROUND
  T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes. The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias.
  
  
  METHODS
  The clinical, pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D. Anderson Cancer Center (MDACC) from 1986 to 2004 were examined.
  
  
  RESULTS
  The most common cytogenetic abnormality was inv(14)(q11;q32), which was present in 7 patients. In all 7 patients, this abnormality was associated with other chromosomal aberrations. Patients treated with alemtuzumab at MDACC had a significantly better response rate (P = 0.02) and survival rate (P = 0.002). There were no significant differences in survival based on Tcl-1 expression or different patterns of CD4 and CD8 expression.
  
  
  CONCLUSIONS
  Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
authors.affiliation: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. fravandi@mdanderson.org
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Dan
authors.initials: D
authors.lastname: Jones
authors.forename: Susan
authors.initials: S
authors.lastname: Lerner
authors.forename: Stefan
authors.initials: S
authors.lastname: Faderl
authors.forename: Alessandra
authors.initials: A
authors.lastname: Ferrajoli
authors.forename: William
authors.initials: W
authors.lastname: Wierda
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.forename: Deborah
authors.initials: D
authors.lastname: Thomas
authors.forename: Charles
authors.initials: C
authors.lastname: Koller
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.forename: Francis
authors.initials: F
authors.lastname: Giles
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.forename: Marco
authors.initials: M
authors.lastname: Herling
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Michael
authors.initials: M
authors.lastname: Keating
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism / Q000473:pathology; D007446:Chromosome Inversion; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human